Evidence mapPaperPMID 37554881Full record

ArticleAnnals of medicine and surgery (2012)2023

The prevalence of dyslipidemia in patients on hemodialysis: a cross-sectional study from Syria.

Yasmeen Kamel Hasan, Mohammad Alsultan, Mohamed Taher Anan, Qussai Hassn, Kassem Basha

Registry-linked trialAbstract read
In one paragraph

Article in Annals of medicine and surgery (2012), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06401122 (Comparison of Dyslipidemia Among Diabetics Versus Non Diabetics in Haemodialysis), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06401122 unknown statusnot on this mapstarted 2024, after this paper: background citation

Comparison of Dyslipidemia Among Diabetics Versus Non Diabetics in Haemodialysis

TypeobservationalSponsorAssiut UniversityRan2024 to 2025Enrolled100ConditionsDyslipidemiasArmshaemodialysis
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yasmeen Kamel HasanDepartment of Nephrology, Al Assad and Al Mouwasat University Hospitals.
Mohammad AlsultanDepartment of Nephrology, Al Assad and Al Mouwasat University Hospitals.ORCID 0000-0001-9113-5338
Mohamed Taher AnanDepartment of Statics, Aleppo University-Faculty of Sciences, Aleppo, Syria.
Qussai HassnDepartment of Nephrology, Al Assad University Hospital.
Kassem BashaDepartment of Nephrology, Al Mouwasat University Hospital, Damascus University-Faculty of Medicine, Damascus.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dyslipidemia is an established risk factor for cardiovascular disease (CVD), which is the main cause of mortality among haemodialysis (HD) patients. We investigate the prevalence and characteristics of dyslipidemia in HD patients. Also, we aimed to study the prediction scores; Framingham risk score (FRS), and the atherosclerotic cardiovascular disease risk score; among this population. Methods: One hundred fifty-three HD patients were enroled in this retrospective cross-sectional study from two HD centres in Syria, from March 2021 to March 2022. Dyslipidemia is considered as follows; hyper-total cholesterol (TC) (≥200 mg/dl), hyper-triglycerides (TG), (≥150 mg/dl), hyper-low-density lipoprotein (LDL) (≥100 mg/dl), hypo-high-density lipoprotein (HDL) (<40 mg/dl), hyper-Non-HDL (≥130 mg/dl). Results: The most prevalent dyslipidemic parameter was low HDL (72.50%) followed by increased TGs (37.30%). TC, LDL, HDL, and Non-HDL showed differences between males and females ( Conclusion: The prevalence of dyslipidemia was high in HD patients in Syria. All lipid parameters except TG showed differences between males and females. Comparisons of lipid parameters with CVD risk stratifications support the need for further studies to prove the benefits of these scores in CVD prediction among the dialysis population.

Indexed as

atherosclerotic cardiovascular disease score (ASCVD)dyslipidemiaFramingham risk score (FRS)haemodialysis (HD)high-density lipoprotein (HDL)total cholesterol (TC)

Identifiers

PMID37554881
PMCPMC10406039

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.